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Abstract
De novo lipogenesis and hypercaloric diets are thought to contribute to increased fat mass, particularly in abdominal fat
depots. CB1 is highly expressed in adipose tissue, and CB1-mediated signalling is associated with stimulation of lipogenesis
and diet-induced obesity, though its contribution to increasing fat deposition in adipose tissue is controversial. Lipogenesis
is regulated by transcription factors such as liver X receptor (LXR), sterol-response element binding protein (SREBP) and
carbohydrate-responsive-element-binding protein (ChREBP). We evaluated the role of CB1 in the gene expression of these
factors and their target genes in relation to lipogenesis in the perirenal adipose tissue (PrAT) of rats fed a high-carbohydrate
diet (HCHD) or a high-fat diet (HFD). Both obesity models showed an up-regulated gene expression of CB1 and Lxra in this
adipose pad. The Srebf-1 and ChREBP gene expressions were down-regulated in HFD but not in HCHD. The expression of
their target genes encoding for lipogenic enzymes showed a decrease in diet-induced obesity and was particularly dramatic
in HFD. In HCHD, CB1 blockade by AM251 reduced the Srebf-1 and ChREBP expression and totally abrogated the remnant
gene expression of their target lipogenic enzymes. The phosphorylated form of the extracellular signal-regulated kinase
(ERK-p), which participates in the CB1-mediated signalling pathway, was markedly present in the PrAT of obese rats. ERK-p
was drastically repressed by AM251 indicating that CB1 is actually functional in PrAT of obese animals, though its activation
loses the ability to stimulate lipogenesis in PrAT of obese rats. Even so, the remnant expression levels of lipogenic
transcription factors found in HCHD-fed rats are still dependent on CB1 activity. Hence, in HCHD-induced obesity, CB1
blockade may help to further potentiate the reduction of lipogenesis in PrAT by means of inducing down-regulation of the
ChREBP and Srebf-1 gene expression, and consequently in the expression of lipogenic enzymes.
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Introduction
Over the last two decades many studies have shown that the
health risks related with obesity are particularly associated with the
enlarged fat depots that closely surround the viscera [1].
Obesogenic diets provoke increased fat storage of white adipose
tissue, mainly in mesenteric (visceral), retroperitoneal (including
perirenal) and perigonadal fat pads [2]. In humans, carbohydrate-
rich diets have the most harmful effect in terms of the increase in
visceral adipose tissue size. Consequently, low-carbohydrate diets
appear more effective at reducing visceral fat than low-fat diets
[3,4].
Dietary carbohydrate is transformed into fat through de novo
lipogenesis [5]. An increase in de novo lipogenesis appears to be an
important contributor to enlarged fat mass [5]. The roles of the
transcription factors liver X receptor (LXR), sterol-response
element binding protein (SREBP) and carbohydrate-responsive-
element-binding protein (ChREBP) are well established in the
regulation of lipogenic gene expression [6]. The LXR transcrip-
tion factor is expressed and activated by endogenous ligands.
Activation of LXR in turn stimulates transcription of the SREBP-1
and CHREBP encoding genes (Srebf-1 and ChREBP) [5,6]. The
enzymes involved in de novo fatty acid synthesis are acetyl-CoA
carboxylase (ACC), fatty acid synthase (FAS), and stearoyl-CoA
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desaturase 1 (SCD1). The transcription factors LXR, SREBP and
ChREBP play an important role in the regulation of the
expression of the genes encoding for these three enzymes FAS,
ACC and SCD1 (Fasn, Acaca, Scd1), leading to triglyceride storage
in hepatocytes and adipocytes [5]. An increase in mRNA levels of
Srebf-1, Fasn and Acaca, and de novo lipogenesis has been described
in the liver and adipose tissue of animals and humans with high fat
diet-induced obesity or after a carbohydrate overfeeding [7,8].
However, lower adipose tissue levels of Srebf-1, Fasn and Acaca
mRNA were also reported in obese compared to lean subjects
[9,10].
Besides its capacity to store and release energy when needed,
the adipose tissue is also considered an endocrine organ secreting
adipokines (leptin and adiponectin), endocannabinoids (ananda-
mide, 2-arachidonoylglycerol), and pro-inflammatory cytokines
(e.g., TNFa, IL-6, IL-8) that act in concert to regulate food intake
and energy balance, mainly through their actions in specific brain
areas [11,12]. Much of the evidence showing the association of
obesity with adipose inflammation comes from the study of visceral
fat depots, including omental and mesenteric, representing a risk
factor for development of the metabolic syndrome and insulin
resistance [13–15]. Also, growing evidence supports that perivas-
cular adipose tissues as perirenal and pericardial fat pads
contribute to exacerbate metabolic syndrome [16]. Even so, the
contribution of each fat depot to the pathophysiology of
complicated obesity is not completely understood. In this regard,
the involvement of endocannabinoids in the development of
metabolic complications associated with obesity deserves particu-
lar attention [17,18]. Experimental data suggest that the
endocannabinoid system is hyper-activated in human abdominal
obesity [19]. Endocannabinoids increase appetite and food intake
through the activation of the highly expressed CB1 receptor in the
mesolimbic and hypothalamic areas of the brain [20,21].
Moreover, CB1 is also widely distributed throughout the body,
especially in the adipose tissue, muscle and liver [22,23]. All these
organs constitute peripheral targets for the action of endocanna-
binoids where they are involved in the regulation of lipid and
carbohydrate metabolism [23–26]. CB1 activation is associated
with stimulation of lipogenesis and diet-induced obesity [17,19].
Excess levels of endocannabinoids exert a negative impact on the
control of food intake, insulin and leptin resistance, glucose
tolerance, dyslipidemia, hypertension, and cardiovascular disor-
ders. Administration of CB1 agonists to lean animals increases the
hepatic levels of SREBP and stimulates transcription of Fasn and
Acaca enzymes and de novo lipogenesis [24]. In contrast, the
administration of CB1 antagonists like rimonabant inhibits
lipogenesis in the liver [24,25,27]. Nevertheless, the influence of
chronic levels of endocannabinoids in the regulation of lipogenesis
in several abdominal fat depots is not fully understood. In a recent
study, chronic cannabis smoking was associated with a high avidity
to carbohydrate intake and with visceral adiposity [28] further
supporting the notion of a close relationship between high levels of
endocannabinoids, a diet rich in carbohydrate and an increase in
visceral adipose tissue size.
The molecular mechanisms underlying CB1-mediated signalling
and regulating lipogenesis are not completely known. The
stimulation of lipogenesis by CB1 probably lies in the coupling
of CB1 to Gi/o proteins. The stimulation of Gi/o proteins blocks
the activity of adenylate cyclase (AC), protein kinase A (PKA) and
adenosine monophosphate-activated protein kinase (AMPK) [29].
PKA and AMPK regulate the lipogenesis pathway negatively by
inducing phosphorylation of LXR (LXR-p) and thereby down-
regulating Srebf-1 and ChREBP and their target genes [27,30–32].
Besides inhibiting their transcription, PKA and AMPK directly
phosphorylate and inactivate SREBP and ChREBP [6,33,34].
CB1 agonists stimulate the lipogenesis pathway by inhibiting
PKA/AMPK through coupling the Gi/o protein [27]. Also, the
CB1 -activated Gi/o proteins stimulate mitogen activated protein
kinase (MAPK) pathways [35], including extracellular signal-
regulated kinases 1/2 (ERK1/2), which have been implicated in
adipogenesis [36]. Recently, the phosphorylation of SREBP by the
ERK1/2 pathway has been related with fatty liver and visceral
obesity [37]. Together, it seems that CB1 activation can stimulate
lipogenesis by inhibiting the PKA/AMPK pathways while
stimulating the MAPK/ERK1/2 pathways through coupling the
Gi/o proteins.
In the present study we evaluated the role of CB1-mediated
activity in perirenal fat -a part of the retroperitoneal depot white
adipose tissue- of lean and diet-induced obese animals focusing on
the study of: i) expression of CB1; ii) expression of the transcription
factors Lxr, Srebf-1 and ChREBP, iii) expression of their lipogenic
target gene enzymes Acaca, Fasn and Scd1, and finally, iv) the CB1-
mediated signalling machinery involved in the expression and
activity of lipogenic factors. To determine the direct involvement
of CB1 in these events we used the CB1 antagonist N-(piperidin-1-
yl)-5-(4-iodophenyl)-1-(2,4 dichlorophenyl-4-methyl-1H-pyrazole-
3-carboxamide), also known as AM251, as a pharmacological tool
[38].
Materials and Methods
Ethics Statement
All experimental procedures with animals were carried out in
strict accordance with the recommendations in the European
Communities directive 2010/63/EU and Spanish legislation (Real
Decreto 53/2013, BOE 34/11370–11421, 2013) regulating the
care and use of laboratory animals. The protocol was approved by
the Ethics Committee for Animal Experiments of the University of
Ma´laga (Permit number: 2011/0001). Male Wistar rats (Charles
Rivers, Barcelona, Spain) were housed in pairs in cages
maintained in standardized conditions of animal facilities at
2062uC room temperature, 4065% relative humidity and a 12 h
light/dark cycle with dawn/dusk effect. At the beginning of the
experiments the rats weighed 200–250 g and were 10–12 weeks
old. Water and food were available ad libitum throughout the
course of the study. Animals were anaesthetized (sodium
pentobarbital, 50 mg/kg body weight, i.p.) in a room separate
from the other experimental animals and sacrificed by decapita-
tion. All efforts were made to minimize animal suffering.
Measurement of Body Weight Gain
Rats (n = 16 per group) were fed ad libitum for 12 weeks with
three different types of diet: a regular chow diet (standard diet,
STD) purchased from Harlam Teklad, Madison WI, a high-fat
diet (HFD, 60% fat diet; D12492), or a high-carbohydrate diet
(HCHD, 70% carbohydrate diet; D12450B) both purchased from
Research Diets Inc. (New Brunswick, NJ, USA). The HFD and
HCHD were used in order to induce obesity. The STD contains
12.12 kJ/g (6% fat, 20% protein), the HFD diet consisted of
21.90 kJ/g (of which, 20% of the metabolizable energy content
was protein, 20% carbohydrates and 60% fat) and the HCHD had
16.09 kJ/g (with 20% protein, 70% carbohydrates and 10% fat).
The HFD contained fat constituted by soybean oil (9.26 kJ% of
total fat content) and lard (90.74 kJ% of total fat content) while the
HCHD contained carbohydrates constituted by corn starch
(45 kcal% of total carbohydrate content), maltodextrin (5 kJ% of
total carbohydrate content) and sucrose (50 kJ% of total carbo-
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hydrate content). The body weight gain was measured every two
days for 12 weeks.
Subchronic AM251 Treatment
After 10 weeks (divergence of weight curves) half of each group
of diet-fed rats (n = 8 per group) received a daily intraperitoneal
(i.p.) injection of vehicle (1 mL/kg of 10% Tocrisolve in saline) or
CB1 receptor inverse agonist AM251 (Tocris Bioscience, Bristol,
UK), at 3 mg/kg in 10% Tocrisolve, over 14 days, while the diets
remained unchanged. The cumulative food/calorie intake and
body weight gain were measured every day during the 14 days of
treatment. Thus, we generated six experimental groups: STD-
vehicle and STD-AM251, HFD-vehicle and HFD-AM251, and
HCHD-vehicle and HCHD-AM251.
Sample Collection, Perirenal Adipose Tissue Extraction
and Histological Examination
Free-feeding animals from the six experimental groups were
anaesthetized (sodium pentobarbital, 50 mg/kg, i.p.) two hours
after the last dose of treatment in a room separate from the other
experimental animals. Blood samples were collected from the
orbital cavity into tubes containing EDTA-2Na (1 mg/mL blood)
and centrifuged (1600 g for 10 min, 4uC), and all plasma samples
were frozen at 280uC for biochemical analysis. Perirenal adipose
tissue (PrAT) was dissected (16 animals per diet group),
immediately frozen in liquid nitrogen and kept at 280uC until
mRNA or protein extraction for subsequent analysis. The PrAT
collected from rats (16 animals per diet group) were also prepared
for histological examination. Samples were cut into small pieces,
immediately fixed in 4% paraformaldehyde for 24 hours, and
embedded in paraffin. Then samples were cut by microtome (5-
mm thick), mounted on D-polylysinated glass slides, deparaffinized
in xylene, and stained with haematoxylin and eosin for the
evaluation of adipocyte size, tissue structure and inflammatory
state by using an optical microscope (Olympus).
RNA Isolation and cDNA Synthesis
Total RNA from PrAT sections (250 mg) was extracted using
Trizol reagent (Invitrogen, Carlsbad, CA) and purified with
Rneasy Mini Kit (QIAGEN GmbH, Hilden, Germany) in
accordance with the manufacturer’s instructions. RNA concen-
tration and purity were determined using a Nanodrop TM
spectrophotometer ND-1000 (Thermo Scientific). RNA (1 mg) was
reverse transcribed with Transcriptor First Strand cDNA Synthe-
sis kit (Roche Applied Science, Mannheim, Germany).
Real-time Quantitative Polymerase Chain Reaction (qPCR)
and Gene Expression Analysis
The expression of genes encoding for rat CB1 (Cnr1), LXRa
(Lxra), SREBP (Srebf-1), ChREBP (ChREBP), ACCa (Acaca), FAS
(Fasn), and SCD1 (Scd1) was measured by qPCR. As reference
genes we used rat ribosomal protein L19 (Rpl19) and rat Sp1
transcription factor (Sp1). Specificity for each primer was tested
using BLAST analyses on National Center for Biotechnology
Information (NCBI) database. The gene symbol, GeneID, primer
sequences, and amplicon length are listed in Table 1. Polymerase
chain reactions were carried out on the CFX96 Real-Time PCR
detection system (Bio-Rad, Hercules, CA) for each cDNA template
and amplified in 15 ml reaction volume containing 1x SYBR
Green PCR master mix (Rox; Applied Science, Mannheim,
Table 1. Primer sequences used for real-time quantitative PCR.
Gene symbol GeneID Primer sequence 59 to 39 GeneBank AN*
Amplicon
length
Cnr1 25248 Fw ACAGCCAGCATGCACAGGGC NM_012784.3 94
Re CGGCGGACGTGTCTGTGGAC
Acaca 60581 Fw TGTGGGCTGGCTGGGGTCAT NM_022193.1 104
Re CGCCCACATGGCCTGACTCG
Fasn 50671 Fw AGTTTCCGTGAGTCCATCCT NM_017332.1 182
Re TCAGGTTTCAGCCCCATAGA
Scd1 246074 Fw GAAGCGAGCAACCGACAG NM_139192.1 71
Re GGTGGTCGTGTAGGAACTGG
Lxra 58852 Fw AGGGCTCCAGGAAGAGATGT NM_031627.2 76
Re CAACTCCGTTGCAGAGTCAG
Srebf-1 78968 Fw CGTGGATGGGGACTGGGCTGTA XM_001075680.2 172
Re CCTGTCTCCATCAGCTGCCCCT
ChREBP 171078 Fw ACAACCCCTGCCTTACACAG FN432819.1 180
Re GAGGTGGCCTAGGTGGTGTA
Reference genes
Rpl-19 81767 Fw TGCCGGAAGAACACCTTG NM_031103.1 121
Re GCAGGATCCTCATCCTTCG
Sp1 24790 Fw GCTATAGCAAACACCCCAGGT NM_012655.1 115
Re GATCAGGGCTGTTCTCTCCTT
*Accesion number.
Fw = Forward.
Rev = Reverse.
doi:10.1371/journal.pone.0090016.t001
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Germany, Roche), and the Forward (Fw) and Reverse (Re)
primers mix. Each assay included, in duplicate, a no-template
control (NTC, water) to verify no amplification of contamination.
Thermocycling parameters were the same for each amplicon
following the supplier’s instructions with one cycle at 95u for
10 min for initial denaturation, followed by 40 cycles of two-steps
at 95u for 10 s and 60u for 30 s, ending with a melting curve.
Specificity was assessed with melting curves.
Raw fluorescence data were submitted to the online Miner tool
(http://www.miner.ewindup.info/) for calculation of Cq and
efficiency values for each experimental set [39]. Cq values were
converted into relative expression values taking into account
amplification efficiencies, inter-run variations, and normalization
factors by means of Biogazelle’s qbase PLUS software (Biogazelle,
Zwijnaarde, Belgium) using both Rpl19 and Sp1 as reference genes
[40]. Repeatability between replicates was accepted when the DCq
value was ,0.7. For all reference and target gene studies, two
independent biological samples of each experimental condition
were evaluated in technical duplicates. Finally, Calibrated
Normalized Relative Quantity (CNRQ) values were exported
from the qbasePLUS software and investigated statistically.
Protein Extraction and Western Blot Analysis
PrAT samples were disrupted in lysis buffer (0.2% SDS, 1 mM
EDTA, 1% NaDOC, 150 mM NaCl, 1% Triton and 50 mM
Tris-HCl pH 7.6) supplemented with a cocktail of protease
inhibitors (Roche Complete tablets). The suspension was shaken
for 30 min at room temperature and centrifuged at 13000 rpm for
45 min at 10uC, recovering the soluble fraction below the fat ring.
Protein concentration was determined by Bradford protein assay.
Protein extracts were diluted 1:1 in 2X sample buffer containing
DTT and boiled for 5 min before submitting to SDS-PAGE.
Samples (50 mg of total proteins each) were resolved in gradient
SDS-PAGE gels (Bio-Rad laboratories, Inc) and blotted onto
nitrocellulose membranes (Bio-Rad). Membranes were blocked in
TBS-T (50 mM Tris-HCl, pH 7.6; 200 mM NaCl, and 0.1%
Tween-20) with 2% BSA. Specific proteins were detected by
incubation in TBS-T, 2% BSA for 2 h with the corresponding
primary antibodies: rabbit anti-ACCab, anti-FAS, anti-SCD1,
anti-PKA, anti-PKAab-Thr198, anti-AMPKa, anti-AMPKa-
Thr172, anti-ERK1/2, anti-ERK1/2-Thr202/Tyr204 and anti-
Actin antibodies, all purchased from Cell Signaling Technology
Inc. (MA, USA). Rabbit anti-LXRa was purchased from Abcam
(Cambridge, UK), and Anti-Adaptin c antibody was from BD
Biosciences (NJ, USA). After extensive washing in TBS-T, anti-
rabbit-HRP conjugated secondary antibody (Promega, Madison,
MI, USA) was added for 1 h. Membranes were subjected to
extensive washings in TBS-T and the specific protein bands were
revealed using the enhanced chemiluminiscence detection system
(Santa Cruz, Biotechnology Inc. CA, USA), in accordance with
the manufacturer’s instructions, and images were visualized in an
Autochemi-UVP Bioimaging System. Bands were quantified by
densitometric analysis performed by ImageJ software (Rasband,
W.S., ImageJ, U.S., National Institutes of Health, Bethesda, MA,
USA, http://imagej.nih.gov/ij, 1997–2012).
Statistical Analysis
All data for graphs and tables are expressed as the mean 6
standard error of the mean (SEM). Statistical analysis of the results
was performed using the computer program GraphPad Prism
version 5.04 (GraphPad Software Inc., San Diego, CA, USA). The
significance of the differences between groups was evaluated by
one-way analysis of variance (ANOVA) followed by a post hoc
analysis for multiple comparisons (Bonferroni’s post hoc) or by one-
tailed Student’s t test with the Welch correction applied when
appropriate (no equal variances assumed) when comparing only
two conditions. A p-value below 0.05 was considered statistically
significant (*, # p,0.05; **, ## p,0.01; ***, ### p,0.001).
Results
Effect of AM251 on Body Weight and CB1 Expression in
PrAT of Rats Fed High-carbohydrate or High-fat Diets for
a Long Time
As expected, rats fed a HCHD or HFD became obese and at
week 10 showed a significant (p,0.001) weight gain over the rats
with normal growth maintained on a regular chow diet (Fig. 1A).
In agreement with our previous results, rats showed a steady
weight gain up to a maximum body weight at week 10 of the
HCHD and HFD, followed by a plateau to the end of the study
[23]. As found previously, a reduction in body net weight was
observed in the two groups of rats fed obesogenic diets as early as
day 4 of AM251 treatment [23,41]. Thus, compared with the
corresponding groups receiving vehicle, at the end of the AM251
treatment (day 14) the body net weight was reduced up to 1.2 g
62.5 in the STD fed rats, 19.4 g 63.2 (p,0.001) in the HCHD-
fed rats and 21.9 g 63.2 (p,0.001) in the HFD-fed rats (Fig. 1B).
We examined the Cnr1 gene expression in PrAT from rats fed a
HCHD and HFD as compared with rats fed a regular chow diet
and the effect of the AM251. The qPCR analysis revealed that
Cnr1 gene expression was significantly increased, by 2.25-fold in
HCHD-fed rats (p,0.05) and 3.40-fold in HFD-fed rats (p,0.001)
treated with vehicle compared with the STD-fed animals treated
with vehicle (Fig. 2). The treatment with AM251 did not
significantly alter the Cnr1 expression levels in any of the
nutritional conditions assayed as compared with the corresponding
matched groups of animals treated with vehicle alone. Therefore,
CB1 blockade did not affect Cnr1 gene expression in PrAT. The
CB1 protein levels in PrAT samples were analyzed by western
blotting. The increase in Cnr1 gene expression observed in
obesogenic conditions was not followed by an increase in protein
levels, which likely indicates a fast recycling rate. Densitometric
analysis revealed that the expression levels of CB1 protein were not
affected by AM251 treatment in any of the diet conditions assayed
(data not shown).
Effect of Obesogenic Diets and AM251 on the LXRa
Expression in PrAT
CB1 activation is implicated in lipogenesis [17,19]. Thus, since
LXRa is the main transcription factor that controls the expression
of lipogenic enzymes [6], we sought to evaluate the impact of CB1
activity on the expression of this factor in different nutritional
conditions. The Lxra gene expression was evaluated in PrAT of
rats fed obesogenic and normal chow diets. As shown in Figure 3A,
the Lxra expression was significantly higher in PrAT from rats fed
either HCHD (p,0.05) or HFD (p,0.001) as compared with rats
fed regular chow. Administration of AM251 significantly reduced
the Lxra expression in HCHD-fed (p,0.01) and HFD-fed rats (p,
0.05) compared to their respective group rats receiving vehicle.
This indicated that the high Lxra expression levels found in rats fed
obesogenic diets were, at least in part, dependent on the CB1-
mediated response.
The western blot analysis revealed that LXRa protein
expression did not appear to parallel the gene expression levels
observed in the different groups of diets and vehicle-treated rats
(Fig. 3B) However, LXRa levels were 0.3060.07-fold (p,0.01) in
the HCHD and 0.4160.10-fold (p,0.05) in the HFD rats treated
with AM251 (Fig. 3B), thus reinforcing the notion that LXRa
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expression is under the control of the CB1-mediated response, at
least in PrAT of obese rats.
Effect of Obesogenic Diets and AM251 on the Srebf-1 and
ChREBP Expression in PrAT
As LXRa is a transcription factor for the Srebf-1 and ChREBP
genes [6,31,42], we then analyzed their gene expression levels in
the different diet groups. As shown in Figure 4A and B, we found
that the expression of Srebf-1 and ChREBP detected in samples
from the HCHD-fed group did not change significantly in
comparison with the STD group. In contrast, a HFD promoted
a significant decrease in the expression of Srebf-1 (p,0.05) and
ChREBP (p,0.01) (Fig. 4A, B). Treatment with AM251 in both the
STD and the HFD groups did not affect significantly the Srebf-1 or
ChREBP expression levels compared with their respective groups
receiving vehicle alone (Fig. 4A, B). Conversely, the expression
levels of Srebf-1 and ChREBP decreased significantly (p,0.01)
under treatment with AM251 in samples from HCHD-fed rats.
This observation suggests that CB1-mediated signalling contributes
to sustain the Srebf-1 and ChREBP gene expression in response to a
diet rich in carbohydrates.
Effect of Obesogenic Diets and AM251 on the Expression
of Lipogenic Enzymes in PrAT
We next analyzed the involvement of CB1 in the gene and
protein expression of the lipogenic enzymes ACC, FAS and SCD1
in PrAT of rats fed the two obesogenic diets and a regular chow
diet. We found that the gene expression levels of these enzymes
(Acaca, Fasn, and Scd1) were dramatically down-regulated (p,
0.001) in PrAT of animals fed HCHD and HFD as compared with
the animals fed regular chow, though in the HCHD condition a
remaining gene expression level of these enzymes was still
measurable by qPCR (Fig. 5A–C). In samples from STD-fed rats,
the treatment with AM251 slightly decreased (p,0.05) the
expression levels of Acaca, Fasn and Scd1 (Fig. 5A–C, respectively).
Likewise, the AM251 treatment further reduced the expression
levels of Acaca (p,0.001), Fasn (p,0.001) and Scd1 (p,0.05)
(Fig. 5A–C, respectively) to undetectable levels in obese rats fed a
HCHD. The initial gene expression of these enzymes in PrAT of
HFD-fed animals was so low that the inhibitory effects of AM251
could hardly be quantified by qPCR (Fig. 5A–C, respectively).
The western blot analysis revealed a remarkable reduction in
protein levels of ACC, FAS (p,0,001) in PrAT of obese rats fed a
HCHD or HFD and vehicle-treated, as compared with the levels
found in samples from STD-fed rats (Fig. 5D). Also, SCD1 protein
levels were drastically reduced in both HCHD and HFD
conditions. Notably, the reduction in these protein levels was
particularly dramatic in HFD conditions (Fig. 5D). Densitometric
assessment of the ACC, FAS and SCD1 bands determined that
treatment with AM251 significantly reduced the expression of
ACC (p,0.001) in the STD group, while no significant changes
were detected in FAS and SCD1 protein expression as compared
with their matched vehicle-treated control groups (Fig. 5D). In the
HCHD-fed group, the AM251 potentiated the reduction in
protein levels of ACC (p,0.001) and FAS (p,0.001) to non-
detectable levels (Fig. 5D), thus indicating that the expression
levels of these lipogenic enzymes are dependent on CB1 activity in
Figure 1. Effect of AM251 on body weight in rats fed standard or obesogenic diets. Net body weight gain was evaluated in rats fed for 10
weeks on a STD, HCHD or HFD. Columns are means6 SEM (n = 16 animals per group). Data were analyzed by one-way ANOVA and Bonferroni’s post-
hoc test. ***p,0.001 denotes significant differences compared with the STD-fed group (A). Relative body weight loss was evaluated in STD, HCHD or
HFD-fed animals after 14-day exposure to vehicle or AM251 (3 mg/kg, daily, i.p.). Columns are means 6 SEM (n = 8 animals per group). Each pair of
treatment groups was analyzed by Student’s t test. ***p,0.001 denotes significant differences compared with the corresponding vehicle-treated
group (B).
doi:10.1371/journal.pone.0090016.g001
Figure 2. Effect of obesogenic diets and AM251 on Cnr1
expression in PrAT. The Cnr1 gene expression was determined by
qPCR analysis in PrAT of STD, HCHD or HFD-fed animals after 14-day
exposure to vehicle or AM251 (3 mg/kg, daily, i.p.). The Cnr1 expression
was normalized to the geometric mean expression of the two reference
genes Rpl19 and Sp1. The average calibrated normalized relative Cnr1
gene expression values in arbitrary units (CNRQ 6 SEM) is shown in the
figure (n = 8 rats per group). Columns are means 6 SEM. Differences
between diets were analyzed by one-way ANOVA and Bonferroni’s post-
hoc test, and comparisons between groups treated with AM251 or
vehicle were analyzed by Student’s t test. #p,0.05 and ###p,0.001
denote significant differences compared with the STD-fed group
treated with vehicle.
doi:10.1371/journal.pone.0090016.g002
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this diet condition. The meagre amounts of ACC, FAS and SCD1
proteins detected in PrAT of HFD-fed rats hardly allowed
measuring the effects of AM251 (Fig. 5D).
Effect of AM251 on CB1 Mediated Signalling in PrAT of
Rats fed Obesogenic Diets for a Long Time
The above results suggested that CB1-mediated signalling
regulates the expression of lipogenic enzymes, probably through
modulating the activity or the expression of their transcription
factors. Moreover, this modulation would depend on the context
of the diet. The activity of LXRa is negatively regulated by
phosphorylation, which depends in part on the activation of the
cAMP/PKA/AMPK pathway [27,30–32]. It is stated that CB1
agonists inhibit the PKA/AMPK pathway through coupling the
Gi/o protein. Consequently, we next sought to investigate the
phosphorylation (activation state) of the kinases PKA and AMPK
in PrAT from animals fed the different diets and treated with
vehicle or AM251. The PKA-p/PKA ratio was analyzed by
western blot. This analysis showed that no significant changes
were detected in the levels of PKA between samples of the
different diet groups, either vehicle-treated or AM251-treated
(Fig. 6A). Indeed, densitometric evaluation of the PKA-total
protein content normalized against Adaptin indicated no varia-
tions between samples of all groups (data not shown). The presence
of a phosphorylated PKA (PKA-p) band was evident in all PrAT
samples (Fig. 6A). In contrast to what was expected, densitometric
analysis showed that the PKA-p band was enhanced 3.95-fold (p,
0.01) in the HCHD group and 2.7-fold (p,0.05) in the HFD
group, compared to the basal levels found in vehicle-treated STD
samples (Fig. 6A). The CB1 blockade by AM251 in any of the
three diet conditions was expected to increase the PKA-p status;
however no significant modification in its phosphorylation levels
was observed, as compared with their respective matched vehicle-
treated diet groups (Fig. 6A).
The AMPK-p/AMPK ratio was also examined in the same blot
for PKA-p/PKA (Fig. 6B). In our assay conditions, no significant
changes were observed in AMPK content when normalized
against Adaptin by densitometry (data not shown). The antibody
used in this study to detect the activated AMPK form recognizes
the Thr172 phosphorylated residue which is phosphorylated by
Figure 3. Effect of obesogenic diets and AM251 on the expression of the Lxra transcription factor in PrAT. The Lxra gene expression
was determined in PrAT of STD, HCHD or HFD-fed animals after 14-day exposure to vehicle or AM251 (3 mg/kg, daily, i.p.). Columns are CNRQ means
6 SEM (n = 8 animals per group). Differences between diets were analyzed by one-way ANOVA and Bonferroni’s post-hoc test, and comparisons
between groups treated with AM251 or vehicle were analyzed by Student’s t test. #p,0.05 and ###p,0.001 denote significant differences
compared with the STD-fed group treated with vehicle. *p,0.05 and **p,0.01 denote significant differences compared with the corresponding
vehicle-treated group (A). Western blot analysis of the LXRa protein was determined in the three diet conditions treated with vehicle alone or AM251
(n = 6 animals per group). Two samples of each group are shown as representative. Relative LXRa protein levels were determined by densitometry
corrected for beta-actin. Levels of LXRa are expressed as the fold over the STD-vehicle treated group (set as 1) as indicated at the bottom of the blot.
*p,0.05 and **p,0.01 denote significant differences compared with the corresponding vehicle-treated group (B).
doi:10.1371/journal.pone.0090016.g003
Figure 4. Effect of obesogenic diets and AM251 on the Srebf-1
and ChREBP gene expression in PrAT. The gene expression of Srebf-
1 (A), and ChREBP (B), was determined in PrAT of STD, HCHD or HFD-fed
animals after 14-day exposure to vehicle or AM251 (3 mg/kg, daily, i.p.).
Columns are CNRQ means 6 SEM (n = 8 animals per group). Differences
between diets were analyzed by one-way ANOVA and Bonferroni’s post-
hoc test, and comparisons between groups treated with AM251 or
vehicle were analyzed by Student’s t test. #p,0.05, ##p,0.01 denote
significant differences compared with the STD-fed group vehicle-
treated. **p,0.01 denote significant differences compared with the
corresponding vehicle-treated group.
doi:10.1371/journal.pone.0090016.g004
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the LKB1 protein that, in turn, is a substrate for PKA. The
analysis by western blot showed no significant variations in
AMPK-p status in any of the three diet conditions in vehicle-
treated or AM251-treated rats (Fig. 6B) and the densitometric
analysis of the AMPK-p/AMPK ratio confirmed this observation
(Fig. 6B).
As ERK1/2 (p42/p44 MAPK) is directly involved in Gi/o-
coupled CB1 receptor-mediated signalling [35], we also evaluated
the phosphorylation status of ERK1/2 (ERK1/2-p) in PrAT
samples. The ERK1/2 and ERK1/2-p protein forms were
analyzed by western blot (Fig. 6C). Assessment of the ERK1/2
total protein content normalized against Adaptin showed no
significant variations between samples from all groups (Fig. 6C).
However, the phosphorylation status of ERK1/2 showed dramatic
variations depending on the group samples (Fig. 6C). Thus,
densitometric analysis revealed that the ERK1/2-p/ERK ratio
was significantly enhanced 17.44-fold (p,0.001) in PrAT from
HCHD animals and 26.06-fold (p,0.001) in HFD animals over
the basal levels found in the vehicle-treated STD group (Fig. 6C).
The extent of the ERK1/2-p dependence on CB1 activity was
analyzed in samples from animals treated with AM251. While no
major differences were found between the vehicle-treated and
Figure 5. Effect of obesogenic diets and AM251 on the lipogenic enzyme gene and protein levels in PrAT. The gene expression of
Acaca (A), Fasn (B) and Scd1 (C) was determined after qPCR analysis in PrAT of STD, HCHD or HFD-fed animals vehicle-treated or AM251-treated
(3 mg/kg, daily, i.p.). Columns are means 6 SEM (n = 6 animals per group). Western blot analysis of protein content of ACC, FAS and SCD1 was
determined in PrAT extracts (D). Two samples of each group are shown as representative. Relative ACC, FAS and SCD1 protein levels were
determined by densitometry corrected for Actin. Protein levels are expressed as the fold over the STD-vehicle treated group (set as 1) for each protein
as indicated at the bottom of the respective blot. Differences between diets were analyzed by one-way ANOVA and Bonferroni’s post-hoc test, and
comparisons between groups treated with AM251 or vehicle were analyzed by Student’s t test. ###p,0.001 denotes significant differences
compared with the STD-fed group treated with vehicle. *p,0.05 and ***p,0.001 denote significant differences compared with the corresponding
vehicle-treated group.
doi:10.1371/journal.pone.0090016.g005
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AM251-treated STD-fed rats, protein analysis showed a dramatic
decrease in the ERK-p/ERK ratio (p,0.001) in those samples
from rats fed obesogenic diets and treated with AM251.
Therefore, this last finding indicates that the ERK-p in PrAT of
obese animals is dependent on CB1-mediated signalling. More-
over, even though the PKA pathway appeared activated, the latter
result clearly indicates that the CB1 signal remains operational in
the PrAT of diet-induced obese animals, but it is biased towards
the ERK-signalling pathway.
Discussion
CB1-mediated signalling is involved in the enhancement of the
lipogenesis pathway in the liver [24,27]. However, the contribu-
tion of CB1 to lipogenesis in different white adipose depots is not
well studied. It is argued that increased circulating levels of
endocannabinoids and CB1 hyperactivity contribute significantly
to increased fat deposits, the hallmark of obesity [19,24,26,43,44].
Accordingly, the CB1 inverse agonist AM251 reduces body weight
in rats fed a diet inducing obesity, and this effect appears to be
related to a reduction in food intake [23,41]. We used a similar
in vivo model to study the impact of CB1 blockade in the expression
of lipogenic genes in PrAT of rats fed two types of hypercaloric
diets. We confirmed that in our experimental conditions the CB1
blockade by AM251 indeed reduced body weight in obese rats fed
a HCHD or a HFD.
The data shown here demonstrate that Cnr1 gene expression is
up-regulated in PrAT after a long period of HCHD or HFD
feeding. This is in contradiction with other results found in human
samples where Cnr1 mRNA levels are decreased in the visceral
adipose tissue of obese individuals [19]. This discrepancy could be
attributable to differences between human and rat endocannabi-
noid physiological functions or most probably to the source of the
adipose tissue. In our case we used perirenal fat which is part of the
retroperitoneal mass of the white adipose tissue. Indeed, the high
Cnr1 gene expression might be a response to chronic circulating
endocannabinoids that promote continuous internalization and
degradation of the CB1 receptor, as has been extensively described
in both humans and animal models [43–46]. Nevertheless, our
data suggest that the CB1 receptor does not regulate its own gene
expression.
Here we show that Lxra gene expression is up-regulated in
PrAT of rats fed obesogenic diets. As obesity can be related to
inflammation in adipose tissue and macrophages express high
levels of LXRa [47,48], we considered the possibility that a high
presence of macrophages could account for the Lxra up-regulation.
However, histological analysis from all groups showed no
inflammation in the PrAT and specific anti-CD68 macrophage
immunostaining proved negative in all samples (data not shown).
Also, it is important to note that macrophages migration is
described to be induced mainly in mesenteric adipose tissue in
obese mice [49]. Therefore, we considered that the increase in
Lxra gene expression comes mainly from adipocytes in the PrAT.
CB1 blockade induced the down-regulation in the expression of
the gene and protein LXRa, thus indicating that this expression is
under the control of CB1.
We found that the Srebf-1 and ChREBP gene expression was
decreased in PrAT of animals fed a HFD. Since these genes are
targets for LXRa, this observation could reflect a failing in the
functionality of the LXRa transcription factor inherent to the
HFD condition. The fact that treatment with AM251 did not
further down-regulate these low levels of Srebf-1 and ChREBP
suggests that CB1 is not functional in PrAT of HFD-fed rats. In the
HCHD groups we did not observe the same effect on these genes.
Indeed, the expression in Srebp-1 and ChREBP genes remained at
levels found in the STD group. Nevertheless, AM251 treatment
induced a significant decrease in their expression, thus suggesting
that in this nutritional condition the expression of Srebf-1 and
ChREBP factors is indeed regulated by CB1-mediated signalling.
These observations are in consonance with the lipogenic
enzyme levels found in the obesogenic diet conditions. The
AM251 treatment in regular chow-fed animals slightly down-
regulated the Acaca, Fasn and Scd1 gene expression, indicating that
CB1-mediated signalling contributes in controlling their gene
expression in PrAT. Our in vivo assays consisted of carbohydrate or
fat over-feeding for a long time, and in these conditions we
observed a drastic down-regulation of Acaca, Fasn and Scd1 gene
expression in PrAT. Our results are in line with recent data
showing the lowered mRNA levels of Acaca and Fasn in the adipose
tissue of human obese subjects as compared with samples from
Figure 6. Effect of obesogenic diets and AM251 on PKA, AMPK
and ERK phosphorylation status in PrAT. Western blot analysis of
the phosphorylation status of the PKA enzyme (A) AMPK (B) and ERK1/2
(C) was determined in PrAT of STD, HCHD or HFD-fed animals treated
with vehicle alone or AM251. Adaptin is shown as equal protein loading
control. The ratio of densitometric values of the PKA-p/PKA, AMPK-p/
AMPK and ERK-p/ERK bands are shown at the bottom of the respective
blots. Differences between diets were analyzed by one-way ANOVA and
Bonferroni’s post-hoc test, and comparisons between groups treated
with AM251 or vehicle were analyzed by Student’s t test. #p,0.05 and
###p,0.001 denote significant differences compared with the STD-
fed group treated with vehicle (set as 1). ***p,0.001 denotes significant
differences compared with the corresponding vehicle-treated group.
doi:10.1371/journal.pone.0090016.g006
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lean subjects [9,10,50]. Nevertheless, our findings further point to
some differences depending on the type of obesogenic diet. Thus,
while in the HFD nutritional condition the expression of these
enzymes is completely ablated, the PrAT samples of the HCHD
group still showed a remnant in the gene expression of these
enzymes. Moreover, these levels are dependent on CB1 since the
AM251 treatment promoted the total down-regulation of Acaca,
Fasn and Scd1 expression.
Our results indicate that the PKA-p status in PrAT of obese
animals is no longer controlled by CB1 signalling since the PKA is
highly phosphorylated and AM251 treatment did not affect it. A
previous report examining the levels of gene expression in adipose
tissue from obese mice revealed a decrease in Gi/o expression
associated with obesity [51] which could account for a permanent
PKA-p state. The increase in PKA-p status that we observed in
PrAT of obese rats likely has a negative repercussion on the LXRa
transcriptional activity that, in turn, would negatively affect the
Srebf-1 and ChREBP gene expression levels. Indeed, we observed a
reduced expression of these genes, at least in HFD-fed rats.
Accordingly, the presence of lipogenic enzymes is dramatically
reduced in terms of gene and protein expression levels in PrAT of
HFD-fed rats. In HCHD conditions, a high PKA-p status was also
observed in PrAT; however, the Srebf-1 and ChREBP gene
expression remained as in normal chow fed rats. Nevertheless,
the reduction in the expression of their target genes Acaca, Fasn y
Scd1 suggests that the activity of the protein forms of SREBP and
ChREBP is probably diminished. Interestingly, CB1 blockade
down-regulated the gene expression of Lxra, Srebf-1 and ChREBP
factors in rats fed a HCHD, and consequently the already lowered
expression of lipogenic enzymes was completely abolished. This
last observation indicates that the gene expression of these factors
and their target genes is still CB1-dependent in the HCHD
condition.
AMPK activation is reported to phosphorylate LXRa, thereby
repressing expression of SREBP [31]. As a result, expression of the
target lipogenic enzyme genes is, in turn, suppressed [27,30,32].
The antibody used in this study to detect AMPK-p recognizes the
Thr172 phosphorylated residue which is phosphorylated via the
PKA pathway. However, we failed to demonstrate changes in this
AMPK-p status in all the nutritional conditions, either vehicle-
treated or AM251-treated groups, and indeed lean and obese rats
showed equal basal levels of this AMPK-p form. Further analysis,
including different antibodies recognizing other phosphorylated
residues in AMPK and additional in vivo experiments for collecting
samples over a time course will be addressed in order to elucidate
this question.
Analysis of the activation state of the kinase ERK, which is
involved in CB1-mediated signalling, also revealed a high ERK-p
status in PrAT of obese animals. Our results demonstrating that
AM251 drastically prevents this ERK phosphorylation point out
that CB1 is indeed operational in PrAT of obese animals. Thus,
our data indicate a simultaneous PKA-p and ERK-p status in
PrAT of animals fed obesogenic diets as opposed to animals fed a
normal chow diet. Since ERK-p is in turn involved in the
activation of SREBP by phosphorylation [37,52,53] these obser-
vations reflect a contradictory signal triggered in PrAT of animals
exposed to diet-induced obesity for a long time; i.e., suppression
and activation of lipogenic gene expression simultaneously, with
the ERK-p status being CB1 dependent.
Overall, our findings suggest that, after a long period with a
high-calorie diet, the CB1-mediated signalling pathway that
specifically induces activation of lipogenesis is seriously compro-
mised without affecting other signalling pathways such as the
ERK1/2 pathway, which is highly activated in PrAT of obese rats.
The specific role of ERK in the CB1-mediated signalling pathway
in obese conditions needs further investigation. In this regard,
some authors have reported the implication of ERK1/2 in visceral
obesity through promoting SREBP phosphorylation and indeed,
inhibition of such phosphorylation protects mice from fatty liver
and visceral obesity [37]. On the other hand, activation of ERK
pathway appears to be involved in adipocyte lipolysis by
phosphorylating the hormone-sensitive lipase (HSL) and increas-
ing the activity of HSL [54]. Further research is needed to
understand how ERK1/2 pathway might affect perirenal fat depot
and its influence on surrounding tissues including liver and kidney.
Finally, the observation that obese rats maintained on a HCHD
still show a remnant lipogenic gene expression in PrAT, and that
this is CB1-dependent, could be one of the causes contributing to
hindering the treatment of obesity induced by the abusive intake of
carbohydrates. Therefore, in such cases, a low carbohydrate diet
combined with CB1-receptor blockade would be advantageous for
the treatment of HCHD-induced abdominal obesity.
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